Iovance Biotherapeautics(IOVA.US)

Last Updated 19:00:00 ET
longbridge loading

Iovance’s Terminated TIL Study Reshapes Expectations for Solid-Tumor Growth

Tip Ranks·
US
IOVA
+2.54%
Tip Ranks·
US
IOVA
+2.54%

Iovance Biotherapeautics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 71.43 M

Earnings Watch·
US
IOVA
+2.54%
Earnings Watch·
US
IOVA
+2.54%

Top 10 US Stock Gainers (5.4)

Top Gainers&Losers·
US
GBTG
-0.32%
US
CRCL
+1.43%
US
CELC
+7.28%
Top Gainers&Losers·
US
GBTG
-0.32%
US
CRCL
+1.43%
US
CELC
+7.28%

CM Management LLC Decreases Stock Holdings in Iovance Biotherapeutics, Inc. $IOVA

Market Beat·
US
IOVA
+2.54%
US
BIB
+4.36%
US
IBBQ
+2.21%
Market Beat·
US
IOVA
+2.54%
US
BIB
+4.36%
US
IBBQ
+2.21%

Will FDA’s RP1 Setback Refocus Iovance Biotherapeutics' (IOVA) Post-Checkpoint Melanoma Narrative?

Simplywall·
US
IOVA
+2.54%
US
PBE
+1.37%
US
IBB
+1.90%
Simplywall·
US
IOVA
+2.54%
US
PBE
+1.37%
US
IBB
+1.90%

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | IOVA Stock News

StockTitan·
US
IOVA
+2.54%
US
BBH
+0.68%
US
PBE
+1.37%
StockTitan·
US
IOVA
+2.54%
US
BBH
+0.68%
US
PBE
+1.37%
© 2026 Longbridge｜Disclaimer